Our products and services are essential components for the research, development and production of new generation medicines as for example vaccines, immuno-oncology therapies, and protein replacement treatments.
Discover our latest initiatives, technology advancements, expansion plans, and our ongoing commitment to research and development of cutting-edge solutions for Cell & Gene Therapies and Nucleic Acids.
Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to 1st Annual Meeting AMM ASCENT in Boston, MA
read moreAnemocyte offers plasmid DNA (pDNA) manufacturing covering R&D, High Quality and GMP needs providing solutions that support every stage of therapy development while ensuring rigorous quality and traceability.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to European Society of Gene & Cell Therapy 2024 in Rome, Italy
read moreQuality assurance (QA) is crucial in the manufacturing of plasmid DNA (pDNA), a key component in gene therapy, vaccine development, genome editing, and synthetic biology.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to Cell & Gene Meeting on the Mesa in Phoenix, Arizona
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to CPHI Milan 2024
read moreDiscover the pivotal role of plasmid DNA sequencing in advancing gene therapy. Learn how this groundbreaking technology is driving the development of novel treatments and shaping the future of biomedicine.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to ATE24 Lisbon, Portugal
read moreDownstream process is fine tuned to recover the soluble fraction of plasmidic DNA, whereas the genomic DNA, proteins polysaccharides and total RNA from E. coli cells are precipitated and removed by depth filtration.
read moreA plasmid is a circular double-stranded DNA molecule that exists separately from the chromosomal DNA within a cell.
read moreThe utilization of plasmid DNA in the production of viral vectors for gene therapy represents a critical advancement in medical biotechnology.
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
